{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-014919","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.986451+00:00","generated_at":"2026-06-06T02:09:56.657062+00:00","sec_items":["1.02"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Larimar Therapeutics terminates at-the-market equity facility with Guggenheim; no shares ever sold","bullets":["Terminated Sales Agreement with Guggenheim Securities effective Feb 13, 2024.","Agreement permitted up to $50M in at-the-market common stock offerings.","No shares of common stock were ever sold under the agreement.","Original agreement date was November 10, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-014919","json":"https://secwatch.observer/filing/0000950170-24-014919.json","markdown":"https://secwatch.observer/filing/0000950170-24-014919.md","text":"https://secwatch.observer/filing/0000950170-24-014919.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024014919/0000950170-24-014919-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024014919/lrmr-20240213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:09:56.657062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"221fb0e0e82cb3097b4b3d72b5d452eb0376439f","claim":"Larimar Therapeutics, Inc. terminated Sales Agreement with Guggenheim Securities, LLC valued at Aggregate offering price of up to $50,000,000; no shares sold under the agreement (effective 2024-02-13).","evidence_excerpt":"On February 13, 2024, Larimar Therapeutics, Inc. (the “ Company ”) gave notice to terminate the Sales Agreement that the Company entered into with Guggenheim Securities, LLC on November 10, 2022 (the “ Sales Agreement ”). Termination of the Sales Agreement was effective February 13, 2024.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024014919/0000950170-24-014919-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Guggenheim Securities, LLC"},{"label":"Value","value":"Aggregate offering price of up to $50,000,000; no shares sold under the agreement"},{"label":"Effective","value":"2024-02-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}